JP5130593B2 - Explosive fermented dietary fiber-containing composition - Google Patents
Explosive fermented dietary fiber-containing composition Download PDFInfo
- Publication number
- JP5130593B2 JP5130593B2 JP2006240332A JP2006240332A JP5130593B2 JP 5130593 B2 JP5130593 B2 JP 5130593B2 JP 2006240332 A JP2006240332 A JP 2006240332A JP 2006240332 A JP2006240332 A JP 2006240332A JP 5130593 B2 JP5130593 B2 JP 5130593B2
- Authority
- JP
- Japan
- Prior art keywords
- dietary fiber
- bagasse
- steamed
- composition
- koji
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、バガス等のヘミセルロース含有植物資源から得られるキシロオリゴ糖、食物繊維等を含有する爆砕発酵処理食物繊維の有効な用途に利用する発明に関し、より詳しくは前記爆砕発酵処理食物繊維を含有する、ヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、ヒト用抗酸化組成物、及び爆砕発酵処理食物繊維を含有する前記用途を有する食品に関する。 The present invention relates to an invention used for effective use of explosive fermented processed dietary fiber containing xylooligosaccharides, dietary fiber, etc. obtained from hemicellulose-containing plant resources such as bagasse, and more specifically, containing the explosive fermented processed dietary fiber. , A composition for improving human intestinal environment, a composition for improving human metabolic syndrome, an antioxidant composition for humans, and a food having the above-mentioned uses, which contains a crushed fermented dietary fiber.
現代社会においては、多くの人が自然界の営みからかけ離れた、特に都会では人工的な環境の中で生活し、また、情報機器、制御機器を使うことが多い仕事や営業等の仕事の過多からくる強いストレス、運動不足、食生活の影響等により、腸内の細菌叢の変化による胃腸炎や肥満体となるヒトが増加している。近年、腸内細菌が、ヒトの健康と深い関わりを有し、ヒトの生理状態に影響を及ぼしていることが明らかにされている。 In modern society, many people are far from nature, especially in urban areas, and in an artificial environment, and because of excessive work such as work and sales that often use information equipment and control equipment. Due to strong stress, lack of exercise, dietary influences, etc., the number of humans who become gastroenteritis and obese due to changes in the bacterial flora in the intestine is increasing. In recent years, it has been clarified that enterobacteria have a deep connection with human health and affect human physiological state.
これらの腸内細菌は食物や薬物に由来するさまざまな物質や内因性物質の代謝に関与していて、ヒトの栄養、生理機能、感染免疫、発癌、老化、薬効等に重要な役割を果たしているといわれており、これらの腸内細菌の中には、ビフィズス菌や乳酸菌のようにヒトの病原菌,ウイルス等に対する感染防御,栄養,有害菌増殖抑制等の面で有利に働く有用菌や、クロストゥリディウム菌,病原性大腸菌のように発癌,肝臓疾患,動脈硬化症,高血圧症,感染症等に関係している有害菌がある。 These enteric bacteria are involved in the metabolism of various substances and endogenous substances derived from food and drugs, and play an important role in human nutrition, physiological function, infectious immunity, carcinogenesis, aging, drug efficacy, etc. Some of these enterobacteria are useful bacteria such as bifidobacteria and lactic acid bacteria that are beneficial in terms of protection against human pathogens, viruses, etc., nutrition, and suppression of growth of harmful bacteria. There are harmful bacteria related to carcinogenesis, liver disease, arteriosclerosis, hypertension, infection, etc.
このようなことから、ヒトの腸内で有用菌を定着させ、増殖させることが最適な腸内細菌叢であると考えられている。このために、腸内の有用菌を増加させるために種々のビフィズス菌製剤や、ヨーグルトなどが開発されているが、ヒトの生体内での胃酸,胆汁酸などの上部消化管のバリヤーの通過、増殖部位としての下部消化管における増殖可能性といった生菌の定着ならびに増殖能力が大きな問題となっている。 For these reasons, it is considered that the optimal intestinal bacterial flora is to establish and proliferate useful bacteria in the human intestine. For this reason, various bifidobacteria preparations and yogurt have been developed to increase useful bacteria in the intestine, but the passage of the upper gastrointestinal barrier such as gastric acid and bile acid in the human body, The establishment of live bacteria such as the possibility of growth in the lower gastrointestinal tract as a growth site and the ability to grow have become major problems.
腸内における有用菌の増殖に必要な因子として最も重要なものは糖類であると考えられ、ラクチュロース,パラチノース,フラクトオリゴ糖,ラフィノース,スタキオース,キシロオリゴ糖などの種々の糖類が有用菌の増殖にとって有効であるとされており、これらを含有した飲食物も提案されているが、これらの糖類は、一部の大腸菌,クロストゥリディウム属細菌等の有害菌に対しても資化性があり、それらの増殖にも関与している。従って、上記糖類が有用菌に選択的に資化されるわけではなく、ヒトの腸内で有用菌の菌数のみが特異的には増加しないのが現状である。以上のことより、未だ満足のいく結果が得られていない。 The most important factor necessary for the growth of useful bacteria in the intestine is considered to be sugars, and various sugars such as lactulose, palatinose, fructooligosaccharides, raffinose, stachyose, and xylooligosaccharides are effective for the growth of useful bacteria. It is said that there are foods and drinks containing these, but these sugars are also assimilating against some harmful bacteria such as Escherichia coli and Clostridium bacteria. It is also involved in the growth of. Therefore, the saccharide is not selectively assimilated by useful bacteria, and the number of useful bacteria is not specifically increased in the human intestine. From the above, satisfactory results have not yet been obtained.
腸内有用菌増殖の向上のため、マンノース直鎖の鎖長が30〜200単位の範囲内に80%以上分布するように低分子化したガラクトマンナンを添加する腸内有用菌増殖効果を有する粉末飲料及びその製造方法(例えば、特許文献1参照)や、フルクトオリゴ糖(FOS)及びガラクトオリゴ糖(GOS)を含む栄養または医薬組成物(例えば、特許文献2参照)や、分子量10,000以上120,000以下であって、その30%(w/v)水溶液の粘度が5〜15mPa・s(25℃,B型粘度計)、1%(w/v)水溶液のpHが5〜7であるポリガラクトース及び/又はポリガラクトース誘導体を含有する腸内環境改善用組成物(例えば、特許文献3参照)が知られている。 In order to improve the growth of useful enteric bacteria, a powder having an effect of proliferating useful enteric bacteria by adding galactomannan having a low molecular weight so that the chain length of the mannose linear chain is distributed in the range of 30 to 200 units or more is 80% or more Beverages and production methods thereof (for example, see Patent Document 1), nutritional or pharmaceutical compositions containing fructooligosaccharides (FOS) and galactooligosaccharides (GOS) (for example, see Patent Document 2), molecular weights of 10,000 to 120, The viscosity of a 30% (w / v) aqueous solution is 5 to 15 mPa · s (25 ° C., B-type viscometer), and the pH of a 1% (w / v) aqueous solution is 5 to 7 A composition for improving the intestinal environment containing galactose and / or a polygalactose derivative (for example, see Patent Document 3) is known.
一方、最近の調査によると、メタボリックシンドローム(Metabolic Syndrome 代謝症候群)の疑いが強いか、その予備群とみられる人が40歳を過ぎると急増し、40〜74歳の男性の約半数に上ることが報告され、女性も同じ年代で5人に1人が当てはまり、該当者は全国で約1960万人と推計されている。メタボリックシンドロームの根本的原因として肥満、運動不足、遺伝因子の3つがあげられ、これらがインスリン抵抗性と結びつき、内臓(腹部)肥満、高脂血症、高血圧、血糖値の上昇などが特徴的である病態となり、こうした病態が動脈硬化、虚血性心疾患(狭心症、心筋梗塞)などの強い危険因子となるといわれ、生活習慣の改善が重要とされている。 On the other hand, according to a recent survey, there is a strong suspicion of metabolic syndrome (Metabolic Syndrome metabolic syndrome), or the number of people who seem to be in the reserve group increases rapidly after the age of 40, and it is about half of men aged 40 to 74 It has been reported that one in five women is the same age, and the estimated number is about 19.6 million nationwide. There are three basic causes of metabolic syndrome: obesity, lack of exercise, and genetic factors, which are associated with insulin resistance, and are characterized by visceral (abdominal) obesity, hyperlipidemia, hypertension, and increased blood sugar levels. It is said that these conditions become strong risk factors such as arteriosclerosis and ischemic heart disease (angina pectoris, myocardial infarction), and improvement of lifestyle is considered important.
メタボリックシンドローム(代謝症候群)の治療及び予防剤としての技術が最近増加しており、特定の化学物質を使用するもの(例えば、特許文献4〜6参照)や、体内の生理活性物質と関連した活性物質を用いるもの(例えば、特許文献7〜10参照)や、繊維と蛋白質からなる、例えば粘稠性可溶性繊維と粘度低下性タンパク質を含む組成物(例えば、特許文献11参照)等が知られている。 The technology as a treatment and prevention agent for metabolic syndrome (metabolic syndrome) has recently increased, and those using specific chemical substances (see, for example, Patent Documents 4 to 6) and activities related to physiologically active substances in the body Materials using substances (for example, see Patent Documents 7 to 10), compositions composed of fibers and proteins, for example, containing viscous soluble fibers and viscosity-reducing proteins (for example, see Patent Document 11), etc. are known. Yes.
ヒトは常時呼吸をし、体に酸素を取り入れている。呼吸によって摂取した酸素のうち約2%〜4%が不安定な不対電子をもつ活性酸素となり活性酸素には、体内に侵入してきた細菌などから身を守る役割もあるが、大量に活性酸素が発生した場合、不飽和脂肪酸が体内で活性酸素によって酸化され、「過酸化脂質」になる。細胞の一番外側にある細胞膜は「不飽和脂肪酸」でできており、その不飽和脂肪酸が酸化して、過酸化脂質となり、細胞膜がボロボロになると、さらに細胞膜内にあるタンパク質までもが巻き込まれて酸化し、もっと有害な二次酸化物ができる。これによって、老化、脳卒中、自己免疫疾患、ガン、白内障、脂肪肝、心筋梗塞、虚血性心疾患、アルツハイマー症候群、糖尿病、糖尿病性腎症、動脈硬化、アレルギー、花粉症のような様々な疾病や皮膚のしわ形成や皮膚の弾力性低下等の老化、炎症、肌の色素沈着が引き起こされている。しかし、体内のSOD(スーパーオキシドディスムターゼ)をはじめ、カタラーゼ、グルタチオン・パーオキシターゼなどの抗酸化物質が備わっており、これによって、この活性酸素を消しさってくれるがこれにも限界がある。 Humans breathe constantly and take oxygen into their bodies. About 2% to 4% of the oxygen ingested by breathing becomes active oxygen with unstable unpaired electrons, and active oxygen also has a role to protect itself from bacteria that have entered the body, but a large amount of active oxygen When this occurs, unsaturated fatty acids are oxidized by active oxygen in the body to become “lipid peroxide”. The cell membrane on the outermost side of the cell is made of "unsaturated fatty acid". When the unsaturated fatty acid is oxidized to become lipid peroxide and the cell membrane becomes tattered, even proteins in the cell membrane are involved. Oxidizes and produces more harmful secondary oxides. As a result, various diseases such as aging, stroke, autoimmune disease, cancer, cataract, fatty liver, myocardial infarction, ischemic heart disease, Alzheimer syndrome, diabetes, diabetic nephropathy, arteriosclerosis, allergy, hay fever and Aging such as skin wrinkle formation and skin elasticity decrease, inflammation, and skin pigmentation are caused. However, it contains antioxidants such as SOD (superoxide dismutase), catalase, and glutathione peroxidase in the body, which eliminates this active oxygen, but there is a limit to this.
抗酸化剤として、例えば、果実等の自然のものを利用する技術として、甘味および抗酸化作用を有する羅漢果配糖体を含有する抗酸化組成物(例えば、特許文献12参照)や、ノブドウ抽出物を有効成分として含有する抗酸化組成物(例えば、特許文献13参照)や、アムラー又はその抽出物を含有する抗酸化組成物(例えば、特許文献14参照)が知られている。 As an antioxidant, for example, as a technology that utilizes natural products such as fruits, an antioxidant composition containing Rahan fruit glycoside having sweetness and antioxidant activity (see, for example, Patent Document 12), and grape extract As an active ingredient, an antioxidant composition (for example, see Patent Document 13) and an antioxidant composition containing Amler or an extract thereof (for example, see Patent Document 14) are known.
本発明の課題は、ヒト腸内有用菌増殖を向上させるがクロストゥリディウム菌,病原性大腸菌のような有害菌を減少させる、安全で副作用のない、ヒト腸内環境改善用組成物や、内臓(腹部)肥満、高脂血症、高血圧、血糖値の上昇などの病態を呈するメタボリックシンドロームの改善用組成物、ヒト用抗酸化組成物、及び前記作用を有する組成物を配合した食品を提供することにある。 The subject of the present invention is a composition for improving the human intestinal environment, which is safe and has no side effects, which reduces the harmful bacteria such as Clostridium bacteria and pathogenic E. coli, while improving the proliferation of useful human intestinal bacteria. Provided are a composition for improving metabolic syndrome exhibiting pathological conditions such as visceral (abdominal) obesity, hyperlipidemia, hypertension, and an increase in blood glucose level, an antioxidant composition for humans, and a food containing the composition having the above-described action. There is to do.
本発明者らは、サトウキビの絞りカスであるバガスの有効利用について鋭意研究しており、その製造方法として、バガスを蒸煮爆砕処理し、この蒸煮爆砕処理バガスに発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、原料となる蒸煮爆砕処理バガスの一部を用いて製麹し、得られた麹に加水し、麹が水に分散した麹分散液に蒸煮爆砕処理バガスを混合し、この混合物の水分含量を調整した後、発酵して爆砕発酵処理バガスを得る方法を先に開発した。そして、得られた爆砕発酵処理バガスには、キシロビオースとキシロトリオ−ス等のキシロオリゴ糖、フェルラ酸等の抗酸化性物質、食物繊維に富むものであった。このように爆砕発酵処理バガスは、糖類、抗酸化性物質及び食物繊維を含有することから、医薬又は有用な食品素材として利用可能性が高いと思われたが、ヒトへ投与し、その結果を確認するまでには至らなかった。その後、実際にヒトへ適用し、種々の医薬効果について鋭意研究した結果、ヒトの腸内環境改善作用、ヒトメタボリックシンドローム改善作用、ヒト用抗酸化作用を有することを確認し、本発明を完成するに至った。 The inventors of the present invention have been diligently researching the effective use of bagasse, which is a sugarcane squeezed residue, and as a production method thereof, the bagasse is steamed and crushed, and the steamed and crushed bagasse is mixed with a fermentation substrate. After adjusting the water content, smoldering with koji mold, smelting using a part of steamed and crushed bagasse as raw material, adding water to the resulting sachet, steaming and smashing into a sardine dispersion in which sushi is dispersed in water A method was first developed in which treated bagasse was mixed and the moisture content of the mixture was adjusted, and then fermented to obtain an explosive fermented bagasse. And the blasting fermentation processing bagasse obtained was rich in xylo-oligosaccharides such as xylobiose and xylotriose, antioxidants such as ferulic acid, and dietary fiber. Thus, it was thought that the explosive fermented bagasse contains saccharides, antioxidants, and dietary fiber, so it was highly likely to be used as a medicine or a useful food material. It did not come to confirm. After that, as a result of actual application to humans and extensive research on various medicinal effects, it was confirmed that they have human intestinal environment improving action, human metabolic syndrome improving action, and human antioxidant action, and the present invention is completed. It came to.
すなわち本発明は、[1]バガスを蒸煮爆砕処理し、この蒸煮爆砕処理物に発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、得られた麹に加水し、麹が水に分散した麹分散液に前記蒸煮爆砕処理物バガスを、製麹に用いた前記蒸煮爆砕処理バガスの5〜10倍量を混合し、この混合物の水分含量を調整した後、発酵することにより得られる爆砕発酵処理食物繊維を含有することを特徴とし、ヒト腸内細菌の中で有用菌を増殖させ、かつ有害菌の増殖を抑制するヒト腸内環境改善用組成物や、[2]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有することを特徴とする上記[1]記載のヒト腸内環境改善用組成物や、[3]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、キシロビオースとキシロトリオースを0.5%以上含有することを特徴とする上記[2]記載のヒト腸内環境改善用組成物や、[4]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、100g中にフェルラ酸を1mg以上含有することを特徴とする上記[1]〜[3]のいずれか記載のヒト腸内環境改善用組成物に関する。
That is, the present invention is [1] steamed bagasse , steamed and crushed, mixed with a fermented substrate, adjusted the water content of the mixture, smelted with koji mold, and added to the resulting koji. In addition, the steamed and crushed and processed bagasse was mixed into the cocoon dispersion in which the cocoon was dispersed in water, and 5 to 10 times the amount of the steamed and crushed and processed bagasse used in the koji making, and the water content of this mixture was adjusted. it features a containing steam explosion fermentation dietary fiber obtained by, grown useful bacteria in the human intestinal bacteria, and growth and human intestinal environment improving composition for suppressing the harmful fungi, [2] steam explosion fermentation dietary fiber, that the above [1] Symbol mounting human intestinal environment-improving composition and which is characterized in containing the dietary fiber than 50% by weight, [3] steam explosion fermentation of dietary fiber Contains 50% by weight or more of dietary fiber, xylobiose And the composition for improving human intestinal environment according to the above [ 2 ], wherein [ 4 ] explosive fermented dietary fiber is 50% by weight or more of dietary fiber The composition for improving human intestinal environment according to any one of [1] to [ 3 ] above, wherein 1 mg or more of ferulic acid is contained in 100 g.
また本発明は、[5]バガスを蒸煮爆砕処理し、この蒸煮爆砕処理物に発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、得られた麹に加水し、麹が水に分散した麹分散液に前記蒸煮爆砕処理物バガスを、製麹に用いた前記蒸煮爆砕処理バガスの5〜10倍量を混合し、この混合物の水分含量を調整した後、発酵することにより得られる爆砕発酵処理食物繊維を含有することを特徴とし、ヒト腸内細菌の中で有用菌を増殖させ、かつ有害菌の増殖を抑制するヒトメタボリックシンドローム改善用組成物や、[6]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有することを特徴とする上記[5]記載のヒトメタボリックシンドローム改善用組成物や、[7]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、キシロビオースとキシロトリオースを0.5%以上含有することを特徴とする上記[6]記載のヒトメタボリックシンドローム改善用組成物に関する。
In the present invention, [ 5 ] bagasse is steamed and crushed, a fermentation substrate is mixed with the steamed and crushed product, the water content of the mixture is adjusted, and the mixture is smelted with koji mold and added to the resulting koji. In addition, the steamed and crushed and processed bagasse was mixed into the cocoon dispersion in which the cocoon was dispersed in water, and 5 to 10 times the amount of the steamed and crushed and processed bagasse used in the koji making, and the water content of this mixture was adjusted. characterized by containing the explosion fermentation dietary fiber obtained by, grown useful bacteria in the human intestinal bacteria and human metabolic syndrome relieving composition to inhibit the growth of harmful bacteria and, [ [6 ] The composition for improving human metabolic syndrome as described in [ 5] above, wherein the explosion-fermented processed dietary fiber contains 50% by weight or more of dietary fiber, and [ 7 ] the exploded fermentation-treated dietary fiber is dietary fiber. 50 layers % By weight or more, relating to the [6] human metabolic syndrome relieving composition, wherein the containing xylobiose and xylotriose 0.5%.
本発明はまた、[8]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、100g中にフェルラ酸を1mg以上含有することを特徴とする上記[5]〜[7]のいずれか記載のヒトメタボリックシンドローム改善用組成物や、[9]バガスを蒸煮爆砕処理し、この蒸煮爆砕処理物に発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、得られた麹に加水し、麹が水に分散した麹分散液に前記蒸煮爆砕処理物バガスを、製麹に用いた前記蒸煮爆砕処理バガスの5〜10倍量を混合し、この混合物の水分含量を調整した後、発酵することにより得られる爆砕発酵処理食物繊維を含有することを特徴とし、ヒト腸内細菌の中で有用菌を増殖させ、かつ有害菌の増殖を抑制するヒト用抗酸化組成物や、[10]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有することを特徴とする上記[9]記載のヒト用抗酸化組成物に関する。
In the present invention, any one of the above [ 5 ] to [ 7 ], wherein the [ 8 ] pyrolysis-fermented dietary fiber contains 50% by weight or more of dietary fiber and 1 mg or more of ferulic acid in 100g. The composition for improving human metabolic syndrome or [9 ] bagasse is steamed and crushed, and the steamed and crushed product is mixed with a fermentation substrate. Water added to the obtained koji, mixed with the koji-cracked processed bagasse in the koji-dispersed solution in which koji was dispersed in water, 5 to 10 times the amount of the above-described steamed and blown-up processed bagasse used for koji making, and the water content of this mixture after adjusting the content, characterized in that it contains a steam explosion fermentation dietary fiber obtained by fermentation, anti for human grown useful bacteria in the human intestinal bacteria, and inhibit the growth of harmful bacteria oxidizing composition or, [10 Explosion granulated fermentation dietary fiber, for human for antioxidant compositions of the above-mentioned [9] Symbol mounting a dietary fiber characterized by containing more than 50 wt%.
さらに本発明は、[11]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、キシロビオースとキシロトリオースを0.5%以上含有することを特徴とする上記[10]記載のヒト用抗酸化組成物や、[12]爆砕発酵処理食物繊維が、食物繊維を50重量%以上含有し、100g中にフェルラ酸を1mg以上含有することを特徴とする上記[9]〜[11]のいずれか記載のヒト用抗酸化組成物や、[13]上記[1]〜[4]のいずれか記載のヒト腸内環境改善用組成物を添加・配合した食品や、[14]上記[5]〜[8]のいずれか記載のヒトメタボリックシンドローム改善用組成物を添加・配合した飲食品や、[15]上記[9]〜[12]のいずれか記載のヒト用抗酸化組成物を添加・配合した飲食品に関する。
Further, the present invention provides the human according to [ 10 ], wherein the [ 11 ] explosive fermented dietary fiber contains 50% by weight or more of dietary fiber and 0.5% or more of xylobiose and xylotriose. [ 9 ] to [ 11 ] above, wherein the antioxidant composition and [ 12 ] explosive fermented dietary fiber contain 50% by weight or more of dietary fiber and 1 mg or more of ferulic acid in 100g. [ 13 ] The food composition in which the composition for improving human intestinal environment according to any one of [1] to [ 4 ] is added and blended, or [ 14 ] above [[ 5 ] to [ 8 ] A food / beverage product to which the composition for improving human metabolic syndrome described in any one of [ 8 ] to [ 8 ] is added, and [ 15 ] the antioxidant composition for humans described in any one of [ 9 ] to [ 12 ] above. Added and blended drink On goods.
本発明の爆砕発酵処理食物繊維を含有する組成物は、何ら副作用を伴うことなくヒト腸内細菌の中でビフィズス菌等の有用菌を増殖させ、クロストゥリディウム菌,病原性大腸菌のような有害菌の増殖を抑制するヒト腸内環境改善作用、内臓(腹部)肥満、高脂血症、高血圧、血糖値の上昇などが特徴的な病態を伴うヒトメタボリックシンドローム改善作用、及びヒト抗酸化作用に顕著な効果を奏することができ、また、黒糖に似たフレーバーを有するので、食品に添加して一般食品として食することができる。 The composition containing the crushed fermented dietary fiber of the present invention allows useful bacteria such as bifidobacteria to grow in human intestinal bacteria without any side effects, such as Clostridium bacteria and pathogenic Escherichia coli. Human intestinal environment improvement action that suppresses the growth of harmful bacteria, visceral (abdominal) obesity, hyperlipidemia, hypertension, human metabolic syndrome improvement action with pathological features characterized by elevated blood glucose level, and human antioxidant action In addition, since it has a flavor similar to brown sugar, it can be added to foods and eaten as general foods.
本発明のヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、ヒト用抗酸化組成物としては、ヘミセルロース含有植物資源を蒸煮爆砕処理し、この蒸煮爆砕処理物に発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、得られた麹に加水し、麹が水に分散した麹分散液に前記蒸煮爆砕処理物を混合し、この混合物の水分含量を調整した後、発酵することにより得られる爆砕発酵処理食物繊維を含有する組成物であれば、発酵処理後の液状物やその乾燥物など特に制限されるものではなく、上記ヘミセルロース含有植物資源としては、サトウキビから砂糖を製造する過程で複製されるサトウキビの圧搾カスであるバガスの他、イネやトウモロコシの芯、木等の不溶性キシランを含む他の植物資源を挙げることができる。以下、ヘミセルロース含有植物資源としてバガスを用いた場合を例にとって説明する。 As the composition for improving human intestinal environment, the composition for improving human metabolic syndrome, and the antioxidant composition for human of the present invention, a hemicellulose-containing plant resource is steamed and crushed, and a fermented substrate is mixed with the steamed and crushed material. After adjusting the water content of the mixture, the mixture is made by koji mold, hydrated into the obtained koji, and the steamed and pyrolyzed product is mixed with the koji dispersion in which koji is dispersed in water. If it is a composition containing a crushed fermented processed dietary fiber obtained by fermentation after adjustment, it is not particularly limited, such as a liquid product after fermentation and its dried product, and as the hemicellulose-containing plant resource, In addition to bagasse, which is a sugar cane squeezed dregs that is replicated in the process of producing sugar from sugarcane, other plant resources that contain insoluble xylan such as rice, corn core and wood It can gel. Hereinafter, a case where bagasse is used as the hemicellulose-containing plant resource will be described as an example.
ヘミセルロース含有植物資源としてバガスを用いた場合、本発明の爆砕発酵処理食物繊維を爆砕発酵処理バガスといい、かかる爆砕発酵処理バガスは、バガスを蒸煮爆砕処理し、この蒸煮爆砕処理物に発酵基質を混合し、この混合物の水分含量を調整した後、麹菌により製麹し、得られた麹に加水し、麹が水に分散した麹分散液に前記蒸煮爆砕処理物を混合し、この混合物の水分含量を調整した後、発酵する方法により得られることになる。 When bagasse is used as a hemicellulose-containing plant resource, the crushed and fermented processed dietary fiber of the present invention is called a crushed and fermented bagasse. After mixing and adjusting the water content of the mixture, the mixture is smelted with koji mold, hydrated into the koji obtained, and the steamed and pyrolyzed product is mixed with koji dispersion in which koji is dispersed in water. After adjusting the content, it is obtained by a method of fermentation.
上記蒸煮爆砕処理としては、耐圧反応容器内で、高温・高圧の水蒸気によりバガスを蒸煮し、キシランをある程度加水分解させた後、耐圧反応容器に設けられたバルブを一気に開放し、瞬間的に大気圧に放出する処理であれば特に制限されず、この蒸煮爆砕処理により、加水分解による化学的反応と、水の断熱膨張による物理的反応の相乗効果によって、バガスを粉砕することができる。この蒸煮爆砕処理条件としては、1.0Mpa〜3.0Mpaで30秒〜10分、好ましくは2.0Mpa〜2.8Mpaで1〜5分、より好ましくは2.4Mpa〜2.6Mpaで60〜80秒を例示することができる。また、バガスをあらかじめ粉砕処理した後、蒸煮爆砕処理を行うことが好ましく、粉砕の程度としては、平均粒径2〜5mm、特に3〜4mm、中でも3.5mmの長さに粗粉砕することが好ましい。 In the above steaming explosion treatment, bagasse is steamed with high-temperature and high-pressure steam in a pressure-resistant reaction vessel, xylan is hydrolyzed to some extent, then the valves provided in the pressure-resistant reaction vessel are opened at once, and instantaneously large. If it is the process discharge | released to atmospheric | air pressure, it will not restrict | limit especially, By this steaming explosion process, bagasse can be grind | pulverized by the synergistic effect of the chemical reaction by hydrolysis and the physical reaction by adiabatic expansion of water. The steaming / explosion treatment conditions are 1.0 Mpa to 3.0 Mpa for 30 seconds to 10 minutes, preferably 2.0 Mpa to 2.8 Mpa for 1 to 5 minutes, more preferably 2.4 Mpa to 2.6 Mpa for 60 to 60 minutes. 80 seconds can be exemplified. In addition, it is preferable to perform steaming and explosion treatment after the bagasse is pulverized in advance, and the degree of pulverization may be roughly pulverized to an average particle diameter of 2 to 5 mm, particularly 3 to 4 mm, and more preferably 3.5 mm. preferable.
蒸煮爆砕処理されたバガスは発酵基質と混合される。かかる発酵基質としては、小麦フスマ、米ヌカ、廃糖蜜等を例示することができるが、小麦フスマが好ましい。例えば、発酵基質として小麦フスマを用いる場合、蒸煮爆砕処理されたバガス100重量部に対して、小麦フスマを1〜50重量部、好ましくは10〜50重量部、より好ましくは40〜45重量部配合することができる。製麹にあたっては、この混合物に加水して、水分含量を調整することが必要であり、水分含量が40〜60%、好ましくは45〜55%、より好ましくは約50%になるように加水する。 Steamed and crushed bagasse is mixed with the fermentation substrate. Examples of the fermentation substrate include wheat bran, rice bran, molasses, etc., but wheat bran is preferable. For example, when wheat bran is used as a fermentation substrate, 1 to 50 parts by weight, preferably 10 to 50 parts by weight, more preferably 40 to 45 parts by weight of wheat bran is added to 100 parts by weight of steamed and blown bagasse. can do. In making the koji, it is necessary to adjust the water content by adding water to this mixture. Water is added so that the water content is 40 to 60%, preferably 45 to 55%, more preferably about 50%. .
製麹に使用する麹菌としては、通常の製麹に用いられる麹菌を挙げることができ、具体的には、アスペルギルス・オリゼー(Aspergillus oryzae)、アスペルギルス・ソーヤ(Aspergillus sojae)等を例示することができる。使用する麹菌としては、キシロオリゴ糖を多く含有する食品素材を得ることができることから、高キシラナーゼ活性を有する株が好ましい。このキシラナーゼによりヘミセルロースからキシロオリゴ糖が産生される。高キシラナーゼ活性株の調製方法として、紫外線や変異誘発剤を用いた変異株の調製方法も利用しうるが、安全性の点で単胞子分離を実施して得られる自然変異株が好ましい。キシラナーゼ活性は、キシランから40℃で1分間に1μmolのキシロースを遊離する活性を1単位として定義し、その測定方法としては、公知方法を利用することができる。高キシラナーゼ活性を有する麹菌としては、この条件により、0.35単位/g以上であることが好ましい。また、キシロオリゴ糖の中でも、キシロビオースやキシロトリオースを主として含むものが、キシロオリゴ糖の中でも胃酸に対する抵抗性が他のオリゴ糖に比べて高いことから、分解されず腸内に到達することから好ましい。爆砕発酵処理バガスに含有されるキシロビオースやキシロトリオースを主成分とするキシロオリゴ糖は、整腸作用等の観点から、3.9%以上が好ましく、かかるキシロビオースやキシロトリオースを主とするキシロオリゴ糖を3.9%以上含む爆砕発酵処理バガスを製造するため、麹菌として、アスペルギルス・ソーヤ(NFRI1147)から単胞子分離を実施して得られるキシラナーゼ活性の高い麹菌を用いることが好ましい。製麹は、28〜32℃、特に30℃で5〜7日培養することにより行うことが好ましい。 As the koji mold used for koji making, koji mold used for ordinary koji making can be mentioned, and specifically, Aspergillus oryzae, Aspergillus sojae and the like can be exemplified. . As the koji mold to be used, a strain having high xylanase activity is preferable because a food material containing a large amount of xylooligosaccharide can be obtained. This xylanase produces xylooligosaccharides from hemicellulose. As a method for preparing a high xylanase active strain, a method for preparing a mutant strain using ultraviolet light or a mutagenic agent may be used, but a natural mutant strain obtained by carrying out single spore isolation is preferable from the viewpoint of safety. The xylanase activity is defined as the activity of releasing 1 μmol of xylose per minute from xylan at 40 ° C., and a known method can be used as the measuring method. As for the koji mold having high xylanase activity, it is preferably 0.35 unit / g or more under these conditions. Among xylo-oligosaccharides, those mainly containing xylo-biose and xylotriose are preferable because xylo-oligosaccharides are more resistant to gastric acid than other oligosaccharides and reach the intestine without being decomposed. The xylo-oligosaccharide mainly composed of xylobiose and xylotriose contained in the pyrolysis-fermented bagasse is preferably 3.9% or more from the viewpoint of intestinal action and the like. The xylooligosaccharide mainly composed of such xylobiose and xylotriose Therefore, it is preferable to use a gonococcus with high xylanase activity obtained by carrying out single spore separation from Aspergillus sojae (NFRI1147). It is preferable to perform koji making by culturing at 28 to 32 ° C., particularly 30 ° C. for 5 to 7 days.
次いで、製麹した麹を水に分散し、この麹分散液に前記蒸煮爆砕処理バガスを混合し、この混合物の水分含量を調整した後、発酵する。麹分散液に混合する蒸煮爆砕処理物として、製麹に用いた蒸煮爆砕処理物の5〜10倍量、好ましくは8〜9倍量を用いることができる。麹分散液に蒸煮爆砕処理バガスを混合した混合物に加水して、水分含量を調整することが必要であり、水分含量が40〜60%、好ましくは45〜55%、より好ましくは略50%になるように加水する。発酵は、28〜32℃、特に30℃で48〜72時間培養することにより行うことが好ましい。発酵後、発酵停止処理を実施することが、過発酵防止の点で好ましい。かかる発酵停止処理としては、80〜100℃の蒸気に30分間暴露する方法を具体的に例示することができる。 Next, the koji made koji is dispersed in water, the steamed and crushed bagasse is mixed with this koji dispersion, and the water content of this mixture is adjusted, followed by fermentation. As the steaming / explosion-treated product to be mixed with the koji dispersion, 5-10 times, preferably 8-9 times the amount of the steaming / explosion-treated product used for koji making can be used. It is necessary to adjust the water content by adding water to a mixture obtained by mixing steamed and crushed bagasse into the koji dispersion, and the water content is 40 to 60%, preferably 45 to 55%, more preferably about 50%. Add water. Fermentation is preferably performed by culturing at 28 to 32 ° C., particularly 30 ° C. for 48 to 72 hours. After fermentation, it is preferable to perform a fermentation stop treatment in terms of preventing overfermentation. As such a fermentation stop treatment, a method of exposing to steam at 80 to 100 ° C. for 30 minutes can be specifically exemplified.
上記爆砕発酵処理バガスとしては、乾燥品が好ましく、特に乾燥微粉末が好ましい。この乾燥微粉末の平均粒径としては、1mm以下、好ましくは500μm以下、より好ましくは200〜300μmを好適に例示することができる。また、本発明の製造方法によって得られる爆砕発酵処理バガスとしては、キシロビオースやキシロトリオースを主成分とするキシロオリゴ糖を3.9%以上含有するものや、フェルラ酸等の抗酸化活性物質を含有して抗酸化活性を示すものや、酵素法により測定した食物繊維を50重量%以上含むものが好ましい。 As the above-mentioned pyrolysis fermentation bagasse, a dry product is preferable, and a dry fine powder is particularly preferable. As an average particle diameter of this dry fine powder, 1 mm or less, Preferably it is 500 micrometers or less, More preferably, 200-300 micrometers can be illustrated suitably. In addition, the pyrolysis-fermented bagasse obtained by the production method of the present invention contains 3.9% or more xylooligosaccharides mainly composed of xylobiose and xylotriose, and contains an antioxidant active substance such as ferulic acid. Thus, those exhibiting antioxidant activity and those containing 50% by weight or more of dietary fiber measured by an enzymatic method are preferred.
次に、爆砕発酵処理食物繊維(爆砕発酵処理バガス)としては、食物繊維を50重量%以上含有するものや、食物繊維を50重量%以上含有し、キシロビオースとキシロトリオースを0.5%以上、好ましくは1%以上、より好ましくは2%以上、中でも3%以上、特に3.9%以上含有するものや、食物繊維を50重量%以上含有し、100g中にフェルラ酸を1mg以上含有するものや、食物繊維を50重量%以上含有し、キシロビオースとキシロトリオースを0.5%以上、好ましくは1%以上、より好ましくは2%以上、中でも3%以上、特に3.9%以上含有し、100g中にフェルラ酸を1mg以上含有するものが好ましい。 Next, explosive fermented processed dietary fiber (explosive fermented processed bagasse) contains 50% by weight or more of dietary fiber, 50% by weight or more of dietary fiber, and 0.5% or more of xylobiose and xylotriose. 1% or more, more preferably 2% or more, especially 3% or more, particularly 3.9% or more, 50% by weight or more of dietary fiber, and 1 mg or more of ferulic acid in 100g And 50% by weight or more of dietary fiber, 0.5% or more of xylobiose and xylotriose, preferably 1% or more, more preferably 2% or more, especially 3% or more, especially 3.9% or more And what contains 1 mg or more of ferulic acid in 100 g is preferable.
本発明のヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、及びヒト用抗酸化組成物は、それぞれ、ヒト腸内環境改善剤、ヒトメタボリックシンドローム改善剤、及びヒト用抗酸化剤として用いることができる。また、本発明のヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、及びヒト用抗酸化組成物は、サプリメントや医薬品として、あるいは食品に添加・配合して摂取することができる。 The composition for improving human intestinal environment, the composition for improving human metabolic syndrome, and the antioxidant composition for human of the present invention are respectively a human intestinal environment improving agent, a human metabolic syndrome improving agent, and a human antioxidant. Can be used as Moreover, the composition for improving human intestinal environment, the composition for improving human metabolic syndrome, and the antioxidant composition for human use of the present invention can be ingested as a supplement or a pharmaceutical, or added to and blended with food.
本発明のヒト腸内環境改善用組成物が有するヒト腸内環境改善作用とは、腸内における有用菌の増殖を促進し、有害菌の増殖を抑制する作用を意味し、このヒト腸内環境改善作用により、ビフィズス菌や乳酸菌のようにヒトの病原菌,ウイルス等に対する感染防御や,栄養,有害菌増殖抑制等の面で有利に働く有用菌の増殖を促進させることができ、一方、クロストゥリディウム菌のように発癌,肝臓疾患,動脈硬化症,高血圧症,自発性感染症等に関係している有害菌の増殖を抑制することができる。また、本発明のヒト腸内環境改善用組成物は、腸内細菌(腸内細菌の数、腸内細菌種のバランス等)を正常な状態にすることの他、腸内細菌叢が正常である状態を積極的に維持すること、あるいは腸内細菌を補うことをも含み、整腸作用、排便への好影響、滋養強壮作用、体力増進・維持、美容健康等広範な作用をも有する。 The human intestinal environment improving action of the composition for improving human intestinal environment of the present invention means an action of promoting the growth of useful bacteria in the intestine and suppressing the growth of harmful bacteria. The improvement action can promote the growth of useful bacteria that are beneficial in terms of defense against human pathogens and viruses such as bifidobacteria and lactic acid bacteria, nutrition, and the prevention of harmful bacteria growth. It can suppress the growth of harmful bacteria related to carcinogenesis, liver disease, arteriosclerosis, hypertension, spontaneous infection, etc. In addition, the composition for improving the human intestinal environment of the present invention has normal intestinal bacterial flora in addition to normalizing intestinal bacteria (the number of intestinal bacteria, the balance of intestinal bacterial species, etc.). It includes maintaining a certain state actively or supplementing intestinal bacteria, and also has a wide range of effects such as intestinal regulation, positive effect on defecation, nourishing tonic, physical strength enhancement / maintenance, and cosmetic health.
本発明のヒトメタボリックシンドローム改善用組成物を用いることにより改善されるヒトメタボリックシンドロームについて説明すると、2002年10月のWHO World Health Reportによれば、世界の全死亡のうち30%までがcardiovascular disease(心血管疾患)に起因するとされ、心血管疾患発症の背景には高血圧,脂質代謝異常,肥満など複数の危険因子が重複して存在し、しかもこれらの危険因子は成因上密接に関連していると考えられている。このように複数の危険因子が重複して高頻度に生じる病態は「メタボリックシンドローム」と呼ばれ,WHOや米国のAdult Treatment Panel IIIによって診断基準が提唱されている。 The human metabolic syndrome that is improved by using the composition for improving human metabolic syndrome of the present invention will be described. According to the WHO World Health Report in October 2002, up to 30% of all deaths in the world accounted for cardiovascular disease ( Cardiovascular disease), and there are multiple risk factors such as hypertension, dyslipidemia and obesity in the background of the onset of cardiovascular disease, and these risk factors are closely related in their pathogenesis It is believed that. A pathological condition in which a plurality of risk factors overlap and occurs frequently is called “metabolic syndrome”, and diagnostic criteria have been proposed by WHO and Adult Treatment Panel III in the United States.
メタボリックシンドロームは、耐糖能異常,高脂血症,高血圧を合併する動脈硬化易発症状態である。高コレステロール血症に対する対策がほぼ確立された現在、動脈硬化疾患の重要な予防ターゲットとなっていることに加え,ライフスタイルが関与する多くの病態を含むことから,多数の分野から注目され、海外でも複数の診断基準が発表されており、病態を正しく認識し,日本人に即した診断基準を作成することが日本人の予防医学上重要である。 Metabolic syndrome is an arteriosclerosis-prone condition associated with impaired glucose tolerance, hyperlipidemia, and hypertension. As countermeasures against hypercholesterolemia are almost established, it has become an important prevention target for arteriosclerosis, and it includes many pathologies involving lifestyles. However, a number of diagnostic criteria have been published, and it is important for Japanese preventive medicine to correctly recognize the pathology and to create diagnostic criteria suitable for the Japanese.
2005年4月に、日本肥満学会、日本動脈硬化学会、日本糖尿病学会、日本高血圧学会、日本循環器学会、日本腎臓病学会、日本血栓止血学会、日本内科学会の8学会が日本におけるメタボリックシンドロームの診断基準をまとめ、公表した。本診断基準では、必須項目となる内臓脂肪蓄積(内臓脂肪面積100平方cm以上)のマーカーとして、ウエスト周囲径が男性で85cm、女性で90cm以上を「要注意」とし、その中で(1)血清脂質異常(トリグリセリド値150mg/dL以上、またはHDLコレステロール値40mg/dL未満)(2)血圧高値(最高血圧130mmHg以上、または最低血圧85mmHg以上)(3)高血糖(空腹時血糖値110mg/dL)の3項目のうち2つ以上を有する場合をメタボリックシンドロームと診断する、と規定している。 In April 2005, Japan Society of Obesity, Japan Arteriosclerosis Society, Japan Diabetes Society, Japan Hypertension Society, Japan Cardiovascular Society, Japan Nephrology Society, Japan Thrombosis and Hematology Society, Japan Society of Internal Medicine, The diagnostic criteria were compiled and published. In this diagnostic standard, as a marker of visceral fat accumulation (visceral fat area of 100 square centimeters or more), which is an essential item, the waist circumference is 85 cm for men and 90 cm or more for women. Serum lipid abnormality (triglyceride level 150 mg / dL or higher, or HDL cholesterol level lower than 40 mg / dL) (2) High blood pressure (highest blood pressure 130 mmHg or higher, or minimum blood pressure 85 mmHg or higher) (3) Hyperglycemia (fasting blood glucose level 110 mg / dL ) Is defined as a diagnosis of metabolic syndrome.
次に、本発明のヒト用抗酸化組成物が有する抗酸化作用について説明する。不対電子を持っている原子や分子をフリーラジカルといい、フリーラジカルは他の物質から電子を奪って安定化するが、電子を奪われた物質(酸化された物質)はフリーラジカルとなってさらに他の物質から電子を奪うようになる。フリーラジカルの代表は活性酸素であり、ヒトが呼吸によって取り込んだ酸素がエネルギーを産生する過程でスーパーオキシド・ラジカル(O2 −)という活性酸素が発生する。ふつうの酸素分子は16個の電子を持っているが、スーパーオキシド・ラジカルは17個の電子をもっており、そのうち1個が不対電子になりフリーラジカルとなる。スーパーオキシド・ラジカルは体内の消去酵素(スーパーオキシド・ジスムターゼ;SOD)によって過酸化水素(H2O2)に変わり、過酸化水素はカタラーゼやグルタチオン・ペルオキシダーゼによって除去される。しかし、活性酸素の一部は微量元素(鉄イオンや銅イオン)やスーパーオキシドと反応して、ヒドロキシルラジカル(・OH)が発生し、ヒドロキシルラジカルも一つの不対電子をもち、その酸化力は活性酸素のなかで最も強力で、細胞を構成する全ての物質をランダムに酸化して障害をおこすといわれている。また、呼吸により取り入れられた酸素の約2%が活性酸素になるといわれており、白血球が有害な細菌を殺す過程でも活性酸素が発生し、活性酸素以外に一酸化窒素も細菌を殺すために白血球やマクロファージという貪食細胞から産生され、一酸化窒素と活性酸素が反応して極めて強力なフリーラジカルが発生することも知られている。さらに、免疫細胞が産生するフリーラジカルは生体防御に必要であるが、炎症における過剰なフリーラジカル生成は、ガン細胞の発生や老化を促進する要因ともなっている。本発明のヒト用抗酸化組成物は抗酸化作用を有し、体内のラジカルを消去する、あるいは体内のラジカルの消去を促進する。 Next, the antioxidant action of the human antioxidant composition of the present invention will be described. An atom or molecule that has an unpaired electron is called a free radical. A free radical takes electrons from other substances and stabilizes them, but a substance that has been deprived of electrons (oxidized substance) becomes a free radical. In addition, it takes electrons from other substances. A representative of free radicals is active oxygen, and active oxygen called superoxide radical (O 2 − ) is generated in the process of producing energy by oxygen taken in by human being breathing. A normal oxygen molecule has 16 electrons, but a superoxide radical has 17 electrons, one of which becomes an unpaired electron and becomes a free radical. Superoxide radicals are converted into hydrogen peroxide (H 2 O 2 ) by the body's elimination enzyme (superoxide dismutase; SOD), and hydrogen peroxide is removed by catalase and glutathione peroxidase. However, some of the active oxygen reacts with trace elements (iron ions and copper ions) and superoxide to generate hydroxyl radicals (.OH), which also has one unpaired electron, and its oxidizing power is It is said to be the most powerful of the active oxygens and cause damage by randomly oxidizing all the substances that make up the cells. In addition, it is said that approximately 2% of oxygen taken in by breathing becomes active oxygen, and active oxygen is generated even in the process of killing harmful bacteria by leukocytes. In addition to active oxygen, nitric oxide also kills leukocytes to kill bacteria. It is also known that it is produced from phagocytic cells called macrophages and macrophages and reacts with nitric oxide and active oxygen to generate extremely powerful free radicals. Furthermore, free radicals produced by immune cells are necessary for biological defense, but excessive free radical production in inflammation is a factor that promotes the generation and aging of cancer cells. The antioxidant composition for humans of the present invention has an antioxidant action, and eliminates radicals in the body or promotes elimination of radicals in the body.
本発明の爆砕発酵処理食物繊維を含有するヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、ヒト用抗酸化組成物は、常法により錠剤、顆粒、カプセル、シロップ等製剤化して、健康サプリメントや医薬品として用いることができる。サプリメントや医薬品として用いる場合、それらの分野で通常用いられている賦形剤を配合することが好ましい。また、摂取量は、ヒトの体重、年齢、性別、症状等により異なり、特に症状に応じて1日当たりの投与量を決定するが、長期に服用することもできる。 The composition for improving human intestinal environment, the composition for improving human metabolic syndrome, and the antioxidant composition for humans containing the crushed fermented processed dietary fiber of the present invention are formulated into tablets, granules, capsules, syrups and the like by conventional methods. Can be used as a health supplement or medicine. When using as a supplement or a pharmaceutical, it is preferable to mix | blend the excipient | filler normally used in those field | areas. The amount of intake varies depending on the human body weight, age, sex, symptoms, etc., and the dose per day is determined according to the symptoms, but can be taken for a long time.
本発明のヒト腸内環境改善用組成物、ヒトメタボリックシンドローム改善用組成物、ヒト用抗酸化組成物や、これらに含まれる爆砕発酵処理食物繊維(爆砕発酵処理バガス)は、黒糖に似たフレーバーを有し、一般食品に含有してもその食品の風味を損なうことがないので、食品に添加・配合して用いることができ、ヒト腸内環境改善作用、ヒトメタボリックシンドローム改善作用、ヒト用抗酸化作用を奏する食品を容易に提供することができる。添加される食品としては、例えば、麺類、飴、クッキー、シリアル類、菓子類(スナック類)、ふりかけ類、畜産加工品類、魚肉加工品類、缶詰類、ジュース類、清涼飲料、栄養ドリンク剤等を挙げることができる。 The composition for improving the human intestinal environment, the composition for improving human metabolic syndrome, the antioxidant composition for humans, and the crushed fermented processed dietary fiber (the crushed fermented processed bagasse) contained in these are flavors similar to brown sugar. Even if it is contained in general foods, it does not impair the flavor of the food, so it can be added to and blended with foods, improving the human intestinal environment, improving human metabolic syndrome, A food product that exhibits an oxidizing action can be easily provided. Examples of foods to be added include noodles, rice cakes, cookies, cereals, confectionery (snacks), sprinkles, processed livestock products, processed fish products, canned foods, juices, soft drinks, nutritional drinks, etc. Can be mentioned.
以下、実施例により本発明をより具体的に説明するが、本発明の技術的範囲はこれらの例示に限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention more concretely, the technical scope of this invention is not limited to these illustrations.
[爆砕発酵処理バガスの製造方法]
(麹菌の選択)
独立行政法人食品総合研究所の保存菌株であるアスペルギルス・ソーヤ(Aspergillus sojae)NFRI1147株の単胞子分離を実施し、各単胞子をPAD培地で生育させ、培養後の培養液中のキシラナーゼ活性を測定することにより、キシラナーゼ活性の高い自然変異株を選択した。3000rpmで10分間の遠心分離後の培養上清1g当たりのキシラナーゼ活性は、単胞子分離を実施する前の0.254Uから、0.351Uに上昇した。
[Production method of explosive fermented bagasse]
(Selection of Neisseria gonorrhoeae)
Single spore isolation of Aspergillus sojae NFRI1147 strain, a stock strain of National Food Research Institute, was conducted, each single spore was grown in PAD medium, and the xylanase activity in the culture broth after culture was measured As a result, natural mutants having high xylanase activity were selected. The xylanase activity per gram of the culture supernatant after centrifugation at 3000 rpm for 10 minutes increased from 0.254 U before performing single spore separation to 0.351 U.
上記キシラナーゼ活性の測定は、1%濃度の可溶性キシラン(シグマ社製)を含む100mMリン酸緩衝液(pH7.0)0.1mlに、同じ緩衝液に適当に希釈した培養上清0.1mlを加え、37℃、10分間反応させ銅試薬1.0mlを添加して反応を停止した。それに0.8mlの同緩衝液を加えて全量を2.0mlとし、生成した還元糖をソモギー・ネルソン(Somogyi-Nelson)法で測定した。すなわち、これを100℃、15分間加熱した後、流水で急冷し次いでネルソン液1.0mlを加え室温で20分間静置して発色させた。そこへ、純水7.0mlを加えて不溶物を遠心分離(3000rpm、10分間)により除去した後、500nmの吸光度を測定した。還元糖量は、キシロースを同様の系で測定して作成した検量線により求めた。なお、培養上清を加える前に銅試薬をあらかじめ加えて同様に発色させたものをブランクとした。また酵素活性単位は、1分間に1mmolの還元糖(キシロースとして)を生成する酵素量を1単位(U)とした。 The above xylanase activity was measured by using 0.1 ml of a 100 mM phosphate buffer solution (pH 7.0) containing 1% concentration of soluble xylan (manufactured by Sigma) and 0.1 ml of culture supernatant appropriately diluted in the same buffer solution. In addition, the mixture was reacted at 37 ° C. for 10 minutes, and 1.0 ml of copper reagent was added to stop the reaction. 0.8 ml of the same buffer was added thereto to make the total volume 2.0 ml, and the produced reducing sugar was measured by the Somogyi-Nelson method. That is, this was heated at 100 ° C. for 15 minutes, then rapidly cooled with running water, and then 1.0 ml of Nelson's solution was added and allowed to stand at room temperature for 20 minutes for color development. Thereto, 7.0 ml of pure water was added and insoluble matters were removed by centrifugation (3000 rpm, 10 minutes), and then the absorbance at 500 nm was measured. The amount of reducing sugar was determined by a calibration curve prepared by measuring xylose in the same system. In addition, before adding culture supernatant, what added the copper reagent beforehand and made it color similarly was made into the blank. The unit of enzyme activity was 1 unit (U), which is the amount of enzyme that produces 1 mmol of reducing sugar (as xylose) per minute.
(製麹工程)
乾燥バガス粉砕機を用いて平均粒径3.5mmの長さに粗粉砕し、反応釜(オートクレーブ)内に収容した後、反応釜に加熱水蒸気を送り込み、2.5Mpa(220℃),70秒間の蒸煮処理を行った後、反応釜から急激に水蒸気を排出し、圧力を瞬時に大気圧にまで戻すことにより爆砕処理を行った。この蒸煮爆砕処理を行ったバガス35kgに小麦フスマ15kgを混合し、水50Lを加水して水分が約50重量%となるように調整した後、単胞子分離により選択した麹菌を接種し、30℃、6日間培養して麹を製造した。
(Steel making process)
After roughly pulverizing to a length of 3.5 mm in average particle size using a dry bagasse pulverizer and storing in a reaction kettle (autoclave), heated steam is fed into the reaction kettle, 2.5 Mpa (220 ° C.), 70 seconds. After performing the steaming process, the steam was rapidly discharged from the reaction kettle, and the pressure was instantaneously returned to atmospheric pressure to perform the explosion process. After mixing 15 kg of wheat bran with 35 kg of bagasse that has been steamed and crushed, 50 L of water is added to adjust the water to about 50% by weight, and then the gonococcus selected by monospore separation is inoculated. The cocoons were produced by culturing for 6 days.
(発酵工程)
この製麹した麹を水70Lに分散し、麹の製造で用いた爆砕処理したバガス300kgに混合した。そして、水分が全体の50重量%となるように加水し調整した後、30℃、60時間の発酵処理した後、80〜100℃の蒸気に30分間暴露して発酵停止処理を行った。この発酵処理物をディスク型乾燥機(月島機械社製)を用い、乾燥温度80〜100℃(品温)で乾燥した後、微粉砕処理をして、平均粒径250μmの爆砕発酵処理バガスとした。この爆砕発酵処理バガスの栄養組成を表1に示す。
(Fermentation process)
This koji mold was dispersed in 70 L of water and mixed with 300 kg of explosive bagasse used in the manufacture of koji. And after adding water and adjusting so that a water | moisture content might be 50 weight% of the whole, after performing the fermentation process of 30 degreeC and 60 hours, it exposed to the 80-100 degreeC vapor | steam for 30 minutes, and performed the fermentation stop process. The fermented product is dried at a drying temperature of 80 to 100 ° C. (product temperature) using a disk-type dryer (manufactured by Tsukishima Kikai Co., Ltd.), then finely pulverized and subjected to an explosion fermented bagasse having an average particle size of 250 μm. did. Table 1 shows the nutritional composition of the crushed and fermented bagasse.
表1に示されるように、爆砕発酵処理バガスは食物繊維に富み、キシロビオースとキシロトリオ−スを約4%含んでいる。なお、キシロビオースやキシロトリオ−スのキシロオリゴ糖の測定は、DX−500を用いHPLC法(日本ダイオネクス社製)に則り測定した。また、別法として、同じHPLC法であるが、カラム:Biorad Aminex Carbohydrate HPX-42A 300×7.8、flow rate1.0ml/minで移動相を水とし、カラム温度80℃にて測定した。 As shown in Table 1, the explosive fermented bagasse is rich in dietary fiber and contains about 4% xylobiose and xylotriose. Xylobiose and xylotriose xylo-oligosaccharides were measured according to HPLC method (manufactured by Nippon Dionex) using DX-500. As another method, the same HPLC method was used, but measurement was performed at a column temperature of 80 ° C. with a column: Biorad Aminex Carbohydrate HPX-42A 300 × 7.8, a flow rate of 1.0 ml / min and water as the mobile phase.
[実験方法]
(乳酸菌培養培地)
LBS(Lactobacillus選択培地)84gと、Lab-lemco powder8gと、蒸留水1000mLとを混合し、該混合物を118℃、15分間オートクレーブにて滅菌し、これに酢酸ナトリウム15g及び酢酸3.7mLを添加し、そのうちの約20mLをシャーレに入れ、固まった後、菌の培養培地とする。
[experimental method]
(Lactic acid bacteria culture medium)
84 g of LBS (Lactobacillus selective medium), 8 g of Lab-lemco powder, and 1000 mL of distilled water were mixed, the mixture was sterilized at 118 ° C. for 15 minutes in an autoclave, and 15 g of sodium acetate and 3.7 mL of acetic acid were added thereto. About 20 mL of the solution is put in a petri dish and solidified, and used as a culture medium for the fungus.
(総嫌気性菌培養培地)
trypticate soy agar30gと、寒天15gと、蒸留水1000mLとを混合し、該混合物を121℃、15分間オートクレーブにて滅菌し、これに馬脱線維血50mLを添加し、そのうちの約20mLをシャーレに入れ、固まった後、菌の培養培地とする。
(Total anaerobic culture medium)
Mix 30 g of trypticate soy agar, 15 g of agar, and 1000 mL of distilled water, sterilize the mixture in an autoclave at 121 ° C. for 15 minutes, add 50 mL of equine defibrinated blood, and put about 20 mL of this in a petri dish. After solidifying, use it as a culture medium for fungi.
(糞便中の腸内細菌培養方法)
糞便1gを滅菌水9mLに溶かし、適宜希釈して培養に用いる。上記の方法により作成した各種の選択培地に、希釈した糞便液50μLを添加し、嫌気的条件で37℃、72時間培養し、生育したコロニーをカウント後、菌数を算出する。
(Method for culturing enteric bacteria in feces)
1 g of feces is dissolved in 9 mL of sterilized water, diluted as appropriate, and used for culture. 50 μL of diluted stool solution is added to various selective media prepared by the above method, cultured at 37 ° C. for 72 hours under anaerobic conditions, and the number of grown colonies is counted, and then the number of bacteria is calculated.
(糞便中のアンモニアの測定)
糞便1gを滅菌水9mLに溶かし、その上澄み液を試験液とし、アンモニア測定キット(アンモニアテストワコー)を用いて測定する。
(Measurement of ammonia in feces)
1 g of stool is dissolved in 9 mL of sterilized water, and the supernatant is used as a test solution and measured using an ammonia measurement kit (Ammonia Test Wako).
[ヒト腸内細菌叢への影響]
年齢34.0±3.5歳の、ビフィズス菌の菌数が少ない女性のボランティア6名に実施例1で製造された爆砕発酵処理バガス100%で打錠したもの10g/日(毎食後14粒)ずつ、2週間連続摂取してもらい、1週間毎に採便し、摂取前、1週間後、及び2週間後の腸内細菌叢の菌数(選択培地にてカウント)と便中のアンモニア含量(アンモニアテストワコーキット使用)を測定した。統計処理としてANOVA法(摂取前と比較)を採用した。
[Effects on human gut microbiota]
10 g / day (14 tablets after each meal) tableted with 100% explosive fermented bagasse prepared in Example 1 to 6 female volunteers of 34.0 ± 3.5 years old with a low Bifidobacterium count ), Ingested for 2 weeks in succession, stool collected every week, before ingestion, after 1 week, and after 2 weeks, the number of intestinal flora (counted in selective medium) and ammonia in stool The content (using ammonia test Wako kit) was measured. ANOVA method (compared with before ingestion) was adopted as statistical processing.
腸内細菌叢における菌の調査としては、総嫌気性菌数、クロストゥリディウム菌数、ビフィドバクテリウム菌数、総嫌気性菌数中のビフィドバクテリウムの含有割合(%)を調べ、その結果を図1の1)、2)、3)、4)に示す。 Bacteria in the intestinal flora were investigated by examining the total anaerobic bacteria count, Clostridium bacteria count, Bifidobacterium count, and Bifidobacterium content (%) in the total anaerobic count. The results are shown in 1), 2), 3) and 4) of FIG.
図1の2)より、腸内の嫌気性有害菌のクロストゥリディウム菌数は、1週目では減少し、一方、図1の3)、4)に示すように、腸内の嫌気性有用菌であるビフィドバクテリウム菌数は、本発明の爆砕発酵処理バガスを摂取して特に1週間後に摂取前と比べて増加していることがわかった。このように、クロストゥリディウムなどの有害菌を減少させ、ビフィドバクテリウムなどの有用菌を増殖させていることから、本発明の爆砕発酵処理バガスはヒト腸内環境改善作用を行っていることは明らかである。 From 2) in FIG. 1, the number of anaerobic harmful bacteria, Clostridium, decreases in the first week, while as shown in 3) and 4) in FIG. It was found that the number of Bifidobacterium, which is a useful bacterium, increased compared to before intake after one week after ingesting the baked fermented bagasse of the present invention. As described above, harmful bacteria such as Clostridium are reduced and useful bacteria such as Bifidobacterium are proliferated, so the explosive fermented bagasse of the present invention has an effect of improving the human intestinal environment. It is clear.
(便中アンモニアへの影響)
同時に便中アンモニア含量を測定した。その結果を図2に示す。図2から明らかなように、便中アンモニアは、徐々に減る傾向にあり、腸内細菌叢はよい環境に変化していることがわかった。
(Influence on fecal ammonia)
At the same time, the stool ammonia content was measured. The result is shown in FIG. As is apparent from FIG. 2, it was found that fecal ammonia tended to gradually decrease, and the intestinal microflora was changed to a good environment.
[爆砕発酵処理食物繊維のヒトでの試飲試験:安全性・有効性]
年齢35.13±10.4歳の男性11名、女性52名の健常者を対象とし、実施例1で製造された爆砕発酵処理バガス100%で打錠したもの10g/日(毎食後14粒)ずつ、4週間連続試飲してもらった。試飲前、2週間、4週間及び試飲停止1週間後に、被験者の便、血液、尿を取り、これらについて測定し、また、アンケート調査を行った。副作用の有無や、便についてはその排便量、排便回数、便の色、便のにおいなどを、また、血液については、血糖値、中性脂肪を、尿については抗酸化活性:尿中8−OHdG(8-hydroxy-2'-deoxyguanosine)測定(参考文献:日本臨床62巻増刊号11,p541−543,2004)を行った。統計処理は、対応のあるANOVA法(試飲前と比較)を採用した。排便量については、図3に示すとおりの結果が得られ、血液の血糖値及び中性脂肪については、図4及び図5に示すとおりの結果が得られた。さらに、抗酸化活性については、図6に示すとおりの結果が得られた。
[Human tasting of explosive fermented dietary fiber: safety and efficacy]
10 g / day (14 tablets after each meal) tableted with 100% explosive fermented bagasse prepared in Example 1 for 11 healthy men of age 35.13 ± 10.4 and 52 females ) Each one for 4 consecutive weeks. Before tasting, 2 weeks, 4 weeks, and 1 week after tasting was stopped, stool, blood, and urine of the subjects were taken and measured, and a questionnaire survey was conducted. Presence / absence of side effects, stool volume, number of stools, stool color, stool odor, etc. for blood, blood sugar level, neutral fat, urine antioxidant activity: urinary 8- OHdG (8-hydroxy-2'-deoxyguanosine) measurement was performed (reference: Japanese clinical volume 62 extra number 11, p541-543, 2004). For statistical processing, the corresponding ANOVA method (compared with before tasting) was adopted. The results shown in FIG. 3 were obtained for the amount of defecation, and the results shown in FIGS. 4 and 5 were obtained for the blood glucose level and neutral fat. Further, the antioxidant activity was obtained as shown in FIG.
図3に示す結果より、排便量は、試飲開始から徐々に増加しており、排便状態がよいことがわかり、本発明の爆砕発酵処理バガスの効果が奏されていることは明らかである。 From the results shown in FIG. 3, it can be seen that the amount of stool is gradually increased from the start of tasting, the state of stool is good, and it is clear that the effect of the blast-fermented bagasse of the present invention is achieved.
次に、図4に示す結果より、血糖値が高い(平均約125mg/dl)6名については、試飲前と比べて2週間後、4週間後、試飲停止1週間後の血糖値のそれぞれは下がっており、これらの血糖値は、正常血糖値70〜109mg/dlの範囲にあり、本発明の爆砕発酵処理バガスは血糖値の上昇を有意に抑制していることがわかった。なお、正常者には何ら影響はなかった。 Next, from the results shown in FIG. 4, the blood glucose levels of 6 persons with high blood glucose levels (average of about 125 mg / dl) after 2 weeks, 4 weeks, and 1 week after stopping tasting are as follows. These blood glucose levels were in the range of normal blood glucose levels of 70 to 109 mg / dl, and it was found that the explosive fermentation-treated bagasse of the present invention significantly suppressed the increase in blood glucose levels. There was no effect on normal subjects.
また、図5に示す結果より、中性脂肪が高めの(平均約190mg/dl)8名については、試飲4週間目では、約125mg/dlまで下がり、この値は有意に下がっていることを示している。因みに正常値は50〜149mg/dlであることから、中性脂肪が高めであった8名の平均は、正常の範囲に下がった結果となった。図に示すとおり、4週目の試飲後、摂取しない1週目では上がっているが、本発明の爆砕発酵処理バガスを摂取することにより減少傾向を示していることは明らかである。 In addition, from the results shown in FIG. 5, 8 people with high neutral fat (average of about 190 mg / dl) decreased to about 125 mg / dl in the fourth week of tasting, and this value was significantly reduced. Show. Incidentally, since the normal value was 50 to 149 mg / dl, the average of the 8 subjects whose neutral fat was high resulted in a decrease in the normal range. As shown in the figure, after the tasting at the 4th week, it rises in the 1st week when it is not ingested, but it is clear that it shows a decreasing tendency by ingesting the baked fermented bagasse of the present invention.
さらに、図6に示す結果より、酸化活性の高めの9名(尿中8−OHdG量が平均値15.7ng/mg以上)は、本発明の爆砕発酵処理バガスを摂取することにより酸化活性は有意に下がり本発明の有効性が確かめられた。なお、副作用を訴えるヒトは誰もいなっかた。 Further, from the results shown in FIG. 6, nine people with higher oxidative activity (urinary 8-OHdG amount is an average value of 15.7 ng / mg or more) show that the oxidative activity is increased by ingesting the baked fermented bagasse of the present invention. The effectiveness of the present invention was confirmed by a significant decrease. No one complained of side effects.
以上のとおり、本発明に係る爆砕発酵処理バガスを摂取することで、前記の病状を改善したことがわかり、即ち、爆砕発酵処理食物繊維含有物はヒトメタボリックシンドローム改善用組成物として有効であることを示すものであった。 As described above, it can be seen that the above-mentioned medical condition has been improved by ingesting the crushed fermented bagasse according to the present invention, that is, the crushed fermented dietary fiber-containing material is effective as a composition for improving human metabolic syndrome. Was shown.
[爆砕発酵処理バガス中の抗酸化活性成分]
実施例1により製造された爆砕発酵処理バガス及び生バガス中のポリフェノール含量を測定した。前記爆砕発酵処理バガス中に同定されたポリフェノール類としては、1)p-hydroxybenzoic acid、2)p-hydroxycinnamic acid、3)ferulic acid(含有量:34.9mg/100g)を挙げることができる。その結果を図7に示す。図7に示す結果より、生バガスに比べて、本発明の爆砕発酵処理バガスはポリフェノール含量が顕著に高いことが明らかであり、このポリフェノールを多く含むことより、抗酸化作用が顕著であることが理解できる。
[Antioxidatively active ingredients in pyrolysis fermented bagasse]
The content of polyphenols in the pyrolysis-fermented bagasse and raw bagasse produced according to Example 1 was measured. Examples of the polyphenols identified in the above-mentioned pyrolysis-treated bagasse include 1) p-hydroxybenzoic acid, 2) p-hydroxycinnamic acid, and 3) ferulic acid (content: 34.9 mg / 100 g). The result is shown in FIG. From the results shown in FIG. 7, it is clear that the pyrolysis-fermented bagasse of the present invention has a significantly higher polyphenol content than raw bagasse, and the antioxidant effect is remarkable due to the high content of this polyphenol. Understandable.
(爆砕発酵処理バガス入り飴)
水飴と砂糖類(白砂糖、ザラメ、黒砂糖等を含む)とを飴材料とし、これに所要量の水を加えて150℃程度に加熱し、全体を撹拌しながら水飴状にした。その水飴状の材料を70℃以下に冷ました後に、未だ粘性がある間に掻き混ぜ又は混練するようにしながら、爆砕発酵処理バガス粉末10重量%を振りかけるようにして添加し、前記バガス粉末が全体に略均等に行き渡るようにする。その後に、飴材料を引き延ばすようにして適宜の型内に入れて成形し、冷ましてから離型して、ドロップ形状の飴菓子を形成し、ドロップ状の飴菓子を得た。
(Boiled bagasse with crushed fermentation)
A syrup and sugar (including white sugar, salam, brown sugar, etc.) were used as a koji material, a required amount of water was added to this and heated to about 150 ° C., and the whole was made into a koji shape while stirring. After cooling the syrup-like material to 70 ° C. or less, it is added by sprinkling 10% by weight of explosive fermented bagasse powder while stirring or kneading while still viscous. To be distributed evenly. Thereafter, the koji material was stretched into a suitable mold and molded, cooled, and then released to form a drop-shaped koji confectionery, thereby obtaining a drop-shaped koji candy.
(爆砕発酵処理バガス入りクッキー)
表2に記載のとおりの原材料及び配合量を用意する。
以下のとおりの常法のクッキーの製造方法を採用して、クッキーを製造する。
(1)フラワー(小麦粉)とベーキングパウダーAを合わせてふるいにかける。
(2)Vマーガリンを室温まで下げて、クリーム状に練る。
(3)グラニュー糖CIM2を数回に分けて(2)に入れ、入れるたびによく混ぜる。
(4)(3)に本発明の醗酵バガス末、そのほかの材料を加え、最後にフラワーを一度に加え、練らないようにして全体を混ぜる。
(5)天板にショートニングを塗り、180℃に温めたオーブンで、12、3分焼く。クッキーは、黒糖の香りがし、味も通常のクッキーと変わりがなく、誰にでも好まれるタイプの菓子であり、毎日のおやつとしても適するものであった。
(Broken cookie with bagasse)
Prepare raw materials and blending amounts as shown in Table 2.
A cookie is manufactured by adopting a conventional method for manufacturing a cookie as follows.
(1) Combine flour (wheat flour) and baking powder A and sift.
(2) Lower the V margarine to room temperature and knead it into a cream.
(3) Divide the granulated sugar CIM 2 into (2) in several batches and mix well each time.
(4) Add the fermented bagasse powder and other ingredients of the present invention to (3), add the flour at the end, and mix the whole so as not to knead.
(5) Apply a shortening to the top board and bake for 12 or 3 minutes in an oven heated to 180 ° C. The cookie has a brown sugar scent and the taste is the same as a normal cookie. It is a type of confectionery that everyone likes and is suitable as a daily snack.
(ドリンク)
表3に記載のとおり、本発明の醗酵バガス末と他の原料を、記載の配合量で、常法の製造方法により粉末ドリンクを製造した。該ドリンクは、粉末タイプでありお湯、水または低脂肪乳などに溶かして飲むことで食物繊維を摂取でき、飲みやすいものであった。
(drink)
As shown in Table 3, a powdered drink was produced by a conventional production method using the fermented bagasse powder of the present invention and other raw materials in the amounts shown. The drink was a powder type, and was able to ingest dietary fiber by being dissolved in hot water, water, low-fat milk or the like, and was easy to drink.
(爆砕発酵処理バガス入りクッキー及びドリンク摂取における効果)
平均年齢39.85±13.74の20人に、実施例6で得られたクッキー13個及び実施例7で得られたドリンクを1食として、1日1食または2食に置き換え2ヶ月間摂取してもらった。摂取後、20人の体重、体脂肪、排便回数、排便量、尿中8−OHdGについて測定した。その結果を表4に示す。
(Effects on ingestion of baked cookies and drinks with pyrolysis fermented bagasse)
20 people with an average age of 39.85 ± 13.74 were replaced with 1 meal or 2 meals a day with 13 cookies obtained in Example 6 and the drink obtained in Example 7 for 2 months. I was ingested. After ingestion, the body weight, body fat, number of defecations, amount of defecation, and urinary 8-OHdG of 20 people were measured. The results are shown in Table 4.
表4に示すとおり、本発明の爆砕発酵処理バガス入りクッキー及びドリンクを所定期間摂取することにより、体重については摂取後より有意に低下し、体脂肪に関しては有意差はないが摂取2ヶ月後で低下傾向にあり、また、排便回数に関しては有意差はないものの増加傾向にあった。さらに、尿中8−OHdGについては基準値異常の人4名については摂取1ヵ月後、2ヵ月後で有意差はないが低下傾向を示した。この結果は、本発明の爆砕発酵処理バガスを食品に添加し、摂取しやすい形態とすることにより、より肥満、高脂血症などメタボリックシンドローム改善作用、ヒト腸内環境改善作用、ヒト抗酸化作用に効果を有することを確認できた。 As shown in Table 4, by taking the baked cookie and drink containing the crushed and fermented fermented bag of the present invention for a predetermined period, the body weight is significantly reduced after ingestion, and there is no significant difference in body fat, but 2 months after ingestion. Although there was a tendency to decrease, there was no significant difference in the number of defecations, but there was an increasing tendency. Furthermore, with respect to urinary 8-OHdG, four people with abnormal reference values showed a downward trend, although there was no significant difference after 1 month and 2 months after ingestion. This result shows that by adding the explosive fermented bagasse of the present invention to foods and making it easy to ingest, metabolic syndrome improvement action such as obesity and hyperlipidemia, human intestinal environment improvement action, human antioxidant action It was confirmed to have an effect.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006240332A JP5130593B2 (en) | 2006-09-05 | 2006-09-05 | Explosive fermented dietary fiber-containing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006240332A JP5130593B2 (en) | 2006-09-05 | 2006-09-05 | Explosive fermented dietary fiber-containing composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008063246A JP2008063246A (en) | 2008-03-21 |
JP5130593B2 true JP5130593B2 (en) | 2013-01-30 |
Family
ID=39286258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006240332A Active JP5130593B2 (en) | 2006-09-05 | 2006-09-05 | Explosive fermented dietary fiber-containing composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5130593B2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008118964A (en) * | 2006-11-15 | 2008-05-29 | Ryukyu Bio Resource Kaihatsu:Kk | Texture improver of noodles |
JP5822423B2 (en) * | 2008-03-28 | 2015-11-24 | 丸善製薬株式会社 | Skin fibroblast proliferation promoter, transglutaminase-1 production promoter, elastase activity inhibitor, MMP-1 activity inhibitor, estrogen-like agent, type I collagen production promoter, and recovery agent from UV-B damage |
JP2010116344A (en) * | 2008-11-13 | 2010-05-27 | Okinawa Satoukibi Kino Kenkyusho:Kk | Oral medicine containing pith fiber of tree and plant and having function of removing intestinal waste and food |
CN104547958A (en) * | 2015-02-09 | 2015-04-29 | 王士国 | Traditional Chinese medicine preparation with effects of promoting digestion and reducing lipid and preparation method |
WO2019168034A1 (en) * | 2018-02-28 | 2019-09-06 | 腸内フローラ移植臨床研究株式会社 | Living microorganism-containing composition and production method thereof |
WO2021039645A1 (en) * | 2019-08-26 | 2021-03-04 | シンバイオシス株式会社 | Biological introduction aid and method of use thereof |
JP7386650B2 (en) * | 2019-08-30 | 2023-11-27 | 株式会社 伊藤園 | Hydrogen gas retention agent, hydrogen gas-containing composition and method for producing the same |
-
2006
- 2006-09-05 JP JP2006240332A patent/JP5130593B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008063246A (en) | 2008-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6203797B1 (en) | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome | |
JP5130593B2 (en) | Explosive fermented dietary fiber-containing composition | |
TWI380823B (en) | An agent for rising concentration of adiponectin | |
EP2481298A2 (en) | Use of plant extracts as prebiotics, compostions and foods containing such extracts | |
KR102315134B1 (en) | Fermented kiwi powder for improving bowel function and method of preparing the same | |
JP2013515051A (en) | Non-fermenting compositions comprising cereal-based fractions and probiotics and their use | |
JP7280069B2 (en) | A composition for preventing or improving functional gastrointestinal disorders, and pharmaceutical compositions and food and drink compositions using the composition for preventing or improving functional gastrointestinal disorders | |
JP2007182395A (en) | Hypolipidic composition | |
EP3202892A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
CN108283285A (en) | A kind of health-care physiotherapeutic food of diabetes | |
JP7516053B2 (en) | Composition, food and drink composition, nutritional composition and formula | |
EP1539779A2 (en) | Condensed palatinose in hydrogenated form | |
KR102513975B1 (en) | Health functional food composition for improving intestinal health containing psyllium hull | |
KR20110116344A (en) | Composition for improving bowel function and relieving constipation containing dietary fiber, oligosaccharide and bacillus coagulans | |
JP5229977B2 (en) | Blood adiponectin concentration increase promoting and / or decreasing inhibitor | |
JP2012001516A (en) | Composition containing coix seed protein having lipid/carbohydrate metabolism improving action | |
JP2009247254A (en) | Health drink | |
KR102037897B1 (en) | Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
US20100008877A1 (en) | Composition for improving skin condition | |
WO2018056284A1 (en) | Composition for improving intestinal flora | |
KR102133015B1 (en) | Health functional food composition for prevention of diabetes | |
JP2021155374A (en) | Agent for increasing intestinal equol producing bacteria, equol production promoting agent, and agent for increasing equol level in the blood | |
KR20100037309A (en) | Pill type manufacturing method of health supporting food | |
CN118077902B (en) | Weight-losing composition containing probiotics and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120717 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121002 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121019 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5130593 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |